New mRNA Vaccine Cuts Neuroblastoma Tumors 70% in Mice

A team in Dublin has created the world's first mRNA vaccine for neuroblastoma, an aggressive childhood cancer, and early results are turning heads in the medical community.

Neuroblastoma accounts for 15% of all cancer deaths in children. Even worse, 80% of kids with aggressive forms of the disease don't respond well to current treatments, leaving families desperate for new options.

Dr. Olga Piskareva and her team at RCSI University of Medicine and Health Sciences took a different approach than typical mRNA vaccines. Instead of using lipid nanoparticles like COVID vaccines do, they created self-assembling peptide nanoparticles called RALA that carry cancer-fighting instructions directly into cells.

The vaccine works by teaching the immune system to recognize and attack a protein called GPC2 that appears on neuroblastoma tumors. When tested in mice, the results exceeded expectations: tumors shrank by 70% compared to unvaccinated animals, and tumor development was delayed by 10 to 11 days.

That delay might sound small, but Piskareva explains it could translate to one or two years in human terms. More importantly, adjusting the dose or vaccination schedule could push that timeline even further.

The research was supported by the Conor Foley Neuroblastoma Cancer Research Foundation, a charity founded by parents who lost their son after a 14-year battle with the disease. That personal connection drives the urgency behind this work.

Why This Inspires

What makes this vaccine truly special is its personalization potential. Doctors could profile a child's specific tumor, design custom mRNA to target it, and have a tailored vaccine ready within weeks.

"The mRNA vaccine technology is like LEGO bricks," Piskareva explains. "By combining different bricks, we can tailor the vaccine to the individual's needs with high precision." Multiple targets can be combined in one treatment, giving the immune system more ways to fight back.

The RALA delivery system also brings practical advantages: it's stable at room temperature, costs less than traditional methods, and doesn't trigger unwanted immune responses. It can carry any size or number of mRNA instructions, making it incredibly flexible.

The team is now planning studies to fine-tune dosing schedules and better understand how the immune response works. They're watching adult mRNA vaccine trials closely to learn from those experiences and avoid delays on the path to testing in children.

"We are at the beginning of the mRNA vaccine development journey, but we have successfully completed the first milestone," says Piskareva. For families facing this devastating diagnosis, that milestone represents something even more valuable: hope.